CD274 and metastatic neoplasm: Tissue-based PD-L1 expression had been considered as one of the predictive biomarkers for immune checkpoint inhibitor therapy; however, PD-L1 expression may vary between primary and metastatic tumors, which could contribute to heterogeneity in treatment responses [32, 33].